Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 486 (CSE: PILL) (OTCQB: CTABF) (NASDAQ: NEPT) (TSX: NEPT) (CSE: BEV) (OTCQB: BVNNF)
Today's podcast sponsored by Cannabis Suisse Corp. (OTC: $CSUI), a fully licensed cannabis cultivation and distribution company in Switzerland
Delta, Kelowna, BC - October 27, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, Cannabis News and Stocks on the Move; Episode 486 (CSE: PILL) (OTCQB: CTABF) (NASDAQ: NEPT) (TSX: NEPT) (CSE:BEV) (OTCQB: BVNNF)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
Today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
In today's podcast we look at a few public and private company announcements.
CANN Global through its management partnership with Medcan Australia Pty Ltd, received an import permit and have placed an initial order for Canntab's products. Canntab will immediately apply for an export permit with Health Canada, which will allow it to fulfill this purchase order. The Company intends to ship its suite of Patented and Patent Pending products, including THC, CBD and THC/CBD combination hard pill formulations to CANN Global before the end of 2020. Once the products are shipped to CANN Global in Australia, the products will be distributed throughout Australia to medical distributors, including Doctors, Pharmacies, and Hospitals.
Applied Cannabis Research ("ACR"), a leading Australian contract research organization focused exclusively on medical cannabis treatments, has launched Australia's largest observational study ever undertaken for medical cannabis. Canntab, through the products it supplies to CANN Global Ltd., which is a direct participant in the study, will be participating in this clinical collaboration with major Australian clinics and hospitals to complete the Cannabinoid Medicine Observational Study ("CMOS") that will collect data from 20,000 patients nationwide over 5 years. CMOS aims to assess the safety and efficacy of medicinal cannabis products for a range of refractory conditions including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health and neurological conditions using cannabis, including Canntab's Hard Pill Cannabinoid Formulations. ACR will lead the study in conjunction with Australia's medical community and key industry partners such as Althea Group Holdings , Cronos Australia , Cymra Life Sciences , Medcan Australia and Cann Global.
"This deal is two years in the making and represents important milestones for our company," explains Larry Latowsky, Chief Executive Officer of Canntab. Mr. Latowsky continues, "it is the first of what will be many international alliances and agreements to export our patented products for distribution through our partners' networks, and it is the first observational clinical study that we are confident will support our vision of our product as unique, effective and the preferred cannabinoid delivery system for many medical symptoms and conditions."
Sholom Feldman, CANN Global's Managing Director says: "We are very excited to progress the launch of Canntab's innovative cannabis-based tablets in Australia which we expect will be very sought-after by Doctors who are looking to prescribe pharmaceutical grade medicinal Cannabis products to their patients. It is our understanding from discussions with medical professionals that it is easier for them to prescribe a uniform dosage tablet produced to pharmaceutical grade standards compared to unreliability of delivery methods used by other products already on the market, giving our product a solid competitive advantage."
The legal cannabis market is expected to be worth US$1.55 billion by 2024 in Australia, New Zealand and the surrounding islands, with medicinal cannabis accounting for approximately 40% of the market.
Australia is expected to account for 79% of the region's overall market by 2024, due to a comparably larger population and higher household disposable income than New Zealand and the islands across the region.
BevCanna Enterprises Inc. (CSE:BEV) (OTCQB:BVNNF) announced that it has successfully completed the R&D and trial production runs of its exclusively licenced award winning line of Keef Beverages and the white-label beverages the Company is producing for State B Beverages.
BevCanna produced and evaluated multiple formulations of the Keef and State B products, including sparkling water, tea-based and soda formats, and multiple bottling formats, including PET and aluminum. Tests were conducted for research and development, shelf stability testing and equipment commissioning purposes, in preparation for the receipt of their Standard Processing License and subsequent product commercialization by Q1 2021.
BevCanna is currently in late-stage discussions to partner with a leading Canadian Licensed Producer ("LP") to distribute its products to provincial cannabis distribution boards through the LP's Health Canada issued Sales License. This will allow BevCanna to begin distribution of its white-label client products, Keef & Cali-Bloom branded products and its own branded products across Canada in Q1 2021, bridging the gap until the Company receives its own Sales License, expected in 2021.
"The inaugural production runs of Keef and State B were extremely successful and we're now moving full steam ahead with our product testing and quality assurance programs," said John Campbell. "We're particularly excited to take the next step with our own branded and exclusively licensed product commercialization efforts, in tandem with our white label partners. We'll be fully prepared to move ahead with production once we receive our Standard Processing License."
BevCanna owns and operates one of the highest-capacity cannabis beverage processing and packaging facilities in Canada and holds the exclusive rights to a pristine spring water aquifer, achieving a bottling capacity of up to 210 million bottles per year. The specialized facility was purpose-built to manufacture BevCanna's infused house brands and those of BevCanna white-label clients launching cannabis 2.0 products. BevCanna's service model allows both cannabis-license holders and non-licensed CPG groups seeking to enter the Canadian cannabis market.
BevCanna's state of the art facility currently is capable of formulating, processing and packaging a range of beverage product formats, including carbonated and non-carbonated aluminum canned and PET beverages. The new beverages will be offered in a variety of sizes, ranging from 60ml-1L, in both standard form and custom vessels.
Neptune Wellness Solutions, Inc. (NASDAQ: NEPT) (TSX: NEPT) announced entering into a supply agreement with the Ontario Cannabis Store (OCS), the wholesaler and sole online retailer for recreational cannabis, for the sale and distribution of Neptune's new proprietary recreational product line, Mood Ring.
This is the second such agreement Neptune has secured through its wholly owned subsidiary 9354-7537 Quebec Inc.1 On Sept. 24, the Company announced it had entered into an agreement with the British Columbia Liquor Distribution Branch (BCLDB), the wholesaler and public retailer of non-medical cannabis products throughout that province.
"This is yet another landmark moment in the cannabis movement, and will allow Neptune to bring the Mood Ring brand - affordable, sustainable and premium cannabis products - to the millions of people who live in that province," said Michael Cammarata, Chief Executive Officer and President of Neptune.
Ontario is Canada's largest market for adult-use cannabis products. The agreement authorizes Neptune to supply Mood Ring products to the OCS for sale and wholesale distribution. The products are anticipated to be available for purchase this fall through the OCS online store.
Additionally, the Mood Ring product line will be available to the 211 licensed private retailers in Ontario. Together with British Columbia, this extends Neptune's reach to 515 retailers in Canada.
The initial Mood Ring product rollout will include quality High CBD Oil, High CBD Capsules, Classic Hashish, and Legacy Hashish. Mood Ring uses Neptune's proprietary cold ethanol extraction process technology to create full spectrum extracts for the Company's CBD products and newly implemented solventless extraction for THC concentrates.
Genome British Columbia (Genome BC) congratulated two BC-led teams for their projects designed to harness the power and potential of bio-innovation to create healthier, more sustainable and prosperous communities.
The two projects, jointly valued at over $10 million, bring together the best of Canadian applied science and commercialization. The first project, CLEan plAnt extractioN SEquencing Diagnostics (CLEANSED) for Clean Grapevines in Canada, is being led by Sudarsana Poojari (Brock University) and Xuekui Zhang (University of Victoria). Their end-user counterparts are Mike Rott (Canadian Food Inspection Agency) and Bill Schenck (Canadian Grape Certification Network). The team is working to develop a rapid, cost effective genomic solution to replace the over 30 molecular and biological tests currently performed on grapevines to look for disease. This one genomic test will speed up the release of virus-free grapevine material from about three years to one year or less, providing rapid access to valuable new varieties. The Canadian Grapevine Certification Network will use this genomic test for monitoring domestically bred vines, ensuring grape growers have faster and more affordable access to clean vines to improve the health of their vineyards.
The second project, Fast-Track Breeding of Powdery Mildew-Resistant Cannabis, is being led by Loren Rieseberg and Marco Todesco (University of British Columbia) with industry partner Greg Baute (Aurora Cannabis). This work will address a need to identify the desirable breeding traits, including resistance to powdery mildew infection, that current cannabis cultivars don't have. Genomic resources will be created that will allow the project team to characterize sources of genetic resistance to powdery mildew and begin to introduce them into Aurora's cannabis breeding program.
"It is an honour to invest in this work and we congratulate all of the successful teams," said Dr. Pascal Spothelfer, President and CEO, Genome BC. "We are realizing the power of genomic science in both of these BC-led projects; for the grapevine industry there is a huge unmet need for rapid disease testing and in the cannabis industry we are supporting the important science behind this growing industry."
Grapevine disease management has been identified by the grape grower and wine industries as a top priority for long-term sector sustainability. Estimated losses of over $23 million are currently incurred annually by Canadian grape growers due to reduced yield of infected grapes and increased fruit rejection by wineries. To replace the currently infected acreage and meet ongoing renewal of vineyards the Canadian industry needs access to 6.7 million domestically produced, virus free vines/year. The grapevine project work will be implemented at the Canadian Food Inspection Agency (CFIA) Sidney Centre for Plant Health (CPH). The proposed methodology will reduce the cost of analysis, and time required, for industry priority varieties imported into Canada, as well as the testing of certified foreign sources destined for commercial planting.
Improved cannabis cultivars will result in reduced losses to pathogen contamination and increase product quality. The breeding pipeline itself will also be used in the future to identify other important production and high-value traits, and to create new cannabis cultivars with superior agronomic performance.
These projects were part of an announcement made yesterday by William Amos, Parliamentary Secretary (Science) on behalf of the Minister of Innovation, Science and Industry Navdeep Bains. They announced $16 million in federal support to 10 new genomics research projects funded through Genome Canada. Provincial governments, businesses and research partners are also investing nearly $41 million in co-funding, for a total investment of $56.4 million in the areas of health, agriculture and the environment.
Once again, today's podcast is sponsored by Cannabis Suisse Corp. (OTC: CSUI ), a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining the AI Eye.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Disclosure: Cannabis Suisse Corp. (OTC: CSUI),is a paid featured company on Investorideas.com
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Download our Mobile App for iPhone and Android